Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · IEX Real-Time Price · USD
12.05
+0.40 (3.43%)
At close: Apr 19, 2024, 4:00 PM
12.10
+0.05 (0.41%)
After-hours: Apr 19, 2024, 5:44 PM EDT
Stoke Therapeutics Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Stoke Therapeutics stock have an average target of 20.43, with a low estimate of 12 and a high estimate of 35. The average target predicts an increase of 69.54% from the current stock price of 12.05.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for STOK stock from 9 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 4 | 4 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 9 | 9 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $22 | Strong Buy | Reiterates | $22 | +82.57% | Apr 11, 2024 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 4, 2024 |
| Wedbush | Wedbush | Buy Maintains $13 → $17 | Buy | Maintains | $13 → $17 | +41.08% | Mar 26, 2024 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $18 → $21 | Strong Buy | Maintains | $18 → $21 | +74.27% | Mar 26, 2024 |
| JP Morgan | JP Morgan | Hold Maintains $6 → $13 | Hold | Maintains | $6 → $13 | +7.88% | Mar 26, 2024 |
Financial Forecast
Revenue This Year
12.58M
from 8.78M
Increased by 43.28%
Revenue Next Year
16.05M
from 12.58M
Increased by 27.55%
EPS This Year
-2.40
from -2.38
EPS Next Year
-2.67
from -2.40
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 21.0M | 63.0M | 78.8M | 201.7M | 303.9M |
| Avg | 12.6M | 16.0M | 34.3M | 81.3M | 191.4M |
| Low | n/a | n/a | n/a | 7.7M | 35.7M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 139.2% | 400.8% | 390.8% | 488.2% | 274.0% |
| Avg | 43.3% | 27.6% | 113.6% | 137.0% | 135.5% |
| Low | - | - | - | -77.4% | -56.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -2.25 | -1.70 | -1.53 | 0.27 | 0.83 |
| Avg | -2.40 | -2.67 | -2.36 | -1.28 | 0.77 |
| Low | -2.57 | -3.38 | -2.78 | -2.49 | 0.70 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.